Read by QxMD icon Read

Japanese Journal of Clinical Oncology

Soichiro Natsume, Tatsuro Yamaguchi, Misato Takao, Takeru Iijima, Rika Wakaume, Keiichi Takahashi, Hiroshi Matsumoto, Daisuke Nakano, Shin-Ichiro Horiguchi, Koichi Koizumi, Michiko Miyaki
Background: The aim of this study was to clarify clinicopathological features, frequencies of molecular biomarkers, and prognoses in Japanese colorectal cancer patients and compare them with right-sided colon cancer (RCC) and left-sided colorectal cancer (LCRC). Methods: We consecutively selected 575 colorectal cancer patients who underwent surgical resection from 2008 to 2011. RCC was located from the cecum to the transverse colon, and LCRC was located from the splenic flexure to the rectum...
May 15, 2018: Japanese Journal of Clinical Oncology
Motonobu Saito, Kouya Shiraishi, Akiteru Goto, Hiroyuki Suzuki, Takashi Kohno, Koji Kono
Targeted therapy against druggable genetic aberrations has shown a significantly positive response rate and longer survival in various cancers, including lung cancer. In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy. On the other hand, targeted therapy against driver gene aberrations has not been adapted yet in small cell lung cancer (SCLC). This is because driver genes and druggable aberrations are rarely identified by next generation sequencing in SCLC...
May 14, 2018: Japanese Journal of Clinical Oncology
Boris Itkin, Samanta Straminsky, Gabriela De Ronato, Daniel Lewi, Adolfo Marantz, Ariel Bardach
Background: Data on long-term prognosis of metastatic GCT (mGCT) is scant. The frequency of spontaneous regressions (SRs) is unknown. We aimed to estimate the prognosis of mGCT. Methods: We searched electronic scientific literature databases and generic Internet from January 1980 to August 2017. After identifying eligible studies we performed descriptive analyses and meta-analyses to estimate overall survival (OS), disease specific survival (DSS) and frequency of SRs in the years before the widespread use of denosumab...
May 5, 2018: Japanese Journal of Clinical Oncology
Wakako Yorozuya, Naotaka Nishiyama, Tetsuya Shindo, Yuki Kyoda, Naoki Itoh, Shintaro Sugita, Tadashi Hasegawa, Naoya Masumori
Objectives: To clarify the efficacy of intravesical Bacillus Calmette-Guérin (BCG) instillation for non-muscle invasive bladder (NMIBC) cancer with variant histology, especially glandular differentiation or squamous differentiation. Materials and methods: From May 1991 through June 2016, 53 patients were diagnosed retrospectively as having NMIBC with variant histology. Among these patients, 47 NMIBC patients with squamous differentiation or glandular differentiation were analyzed for this study...
May 4, 2018: Japanese Journal of Clinical Oncology
Eun Kyung Paik, Mi-Sook Kim, Young-Seok Seo, Won Jang, Jin-Kyu Kang, Chul-Koo Cho, Hyung Jun Yoo
Background: There is growing interest in the use of stereotactic ablative radiotherapy (SABR) for oligometastases. However, extreme caution should be exercised in treating tumors closely located to organs at risk (OARs) with SABR. To reduce complications, we have applied split-course SABR to oligometastases closely located to OARs or to those being retreated with radiotherapy. Methods: We retrospectively reviewed the records of patients with oligometastases who were treated with planned split-course SABR between January 2012 and December 2016...
May 2, 2018: Japanese Journal of Clinical Oncology
Kouki Kuwabara, Okihide Suzuki, Noriyasu Chika, Kensuke Kumamoto, Toshiharu Minabe, Tomoo Fukuda, Eiichi Arai, Jun-Ichi Tamaru, Kiwamu Akagi, Hidetaka Eguchi, Yasushi Okazaki, Hideyuki Ishida
Background: Muir-Torre syndrome (MTS) is currently considered as a clinical variant of Lynch syndrome (LS). The clinical significance of the screening of patients with MTS-associated cutaneous tumors for the identification of LS has not yet been established. In addition, the prevalence and molecular characteristics of mismatch repair (MMR) protein deficiency in such tumors has scarcely been investigated in the Japanese population. Methods: Immunohistochemistry (IHC) for MMR proteins (MLH1, MSH2, MSH6 and PMS2) was performed in formalin-fixed paraffin-embedded sections prepared from 16 sebaceous neoplasms (SNs) resected from 13 patients and 32 keratoacanthomas (KAs) resected from 31 patients at our institution between January 2005 and March 2014...
April 28, 2018: Japanese Journal of Clinical Oncology
Yaolin Xu, Xi Guo, Yue Fan, Dansong Wang, Wenchuan Wu, Lili Wu, Tianshu Liu, Bei Xu, Yi Feng, Yan Wang, Wenhui Lou, Yuhong Zhou
Objective: To compare efficacy and safety of nabpaclitaxel plus S-1 (AS) with gemcitabine plus S-1 (GS) as first-line treatment for metastatic pancreatic cancer. Methods: We conducted a retrospective cohort, single-institution analysis by reviewing medical records of 38 patients who received either AS (nabpaclitaxel 125 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) or GS (gemcitabine 1000 mg/m2 on Days 1, 8 and S-1 80 mg/m2 on Days 1 to 14) chemotherapy. Results: AS was associated with a prolonged median time to progression (TTP; 7...
April 28, 2018: Japanese Journal of Clinical Oncology
Teppei Okubo, Koji Mitsuzuka, Takuya Koie, Senji Hoshi, Shigeki Matsuo, Seiichi Saito, Norihiko Tsuchiya, Tomonori Habuchi, Chikara Ohyama, Yoichi Arai
Background: Salvage treatments for biochemical relapse (BCR) after radical prostatectomy (RP) have several problems in terms of indications or adverse events. We studied the possibility of 2 years of bicalutamide monotherapy for BCR after RP. Methods: Patients who showed BCR (prostate-specific antigen (PSA) ≥ 0.2 ng/ml) after RP were recruited. Protocol treatment was planned as 2 years of bicalutamide (80 mg/day) followed by observation. Protocol treatment failure was defined as PSA re-elevation of ≥0...
April 28, 2018: Japanese Journal of Clinical Oncology
Emi Yamaga, Akira Toriihara, Shin Nakamura, Sakurako Asai, Tomoyuki Fujioka, Ryoichi Yoshimura, Yasuyuki Michi, Hiroyuki Harada, Ukihide Tateishi
Background: Positron emission tomography with 2-deoxy-2-[18F] fluoro-d-glucose integrated with computed tomography (FDG-PET/CT) is a useful method to evaluate patients with oral squamous cell carcinoma (OSCC). However, the prognostic significance of FDG-PET/CT for assessing early OSCC remains unclear. Methods: Pretreatment FDG-PET/CT of 205 consecutive patients (125 men, 80 women, mean age 59.7 year old) with early OSCC (cT1-2N0M0) between June 2010 and December 2014 were retrospectively analyzed...
April 28, 2018: Japanese Journal of Clinical Oncology
Yosuke Kubota, Tatsuo Akechi, Toru Okuyama
Many nurses are not confident in management of psychological distress in cancer patients. We developed a brief psycho-oncology training program for general nurses, and explored the usefulness of the program preliminary. Seventy-two nurses in 17 designated cancer hospitals received a 4-h program comprising an e-learning lecture on assessment and management of normal psychological responses to cancer and an onsite workshop, including a role-play exercise and group work. Primary outcomes were changes in self-reported confidence, knowledge and attitudes toward caring for patients with normal psychological response between pre-training and post-training...
April 28, 2018: Japanese Journal of Clinical Oncology
Satoshi Kinoshita, Toshihiro Nishizawa, Shigeo Banno, Toshio Uraoka
No abstract text is available yet for this article.
April 25, 2018: Japanese Journal of Clinical Oncology
Shogo Shinohara, Shinji Takebayashi, Masahiro Kikuchi, Tetsuhiko Michida, Kazuki Hayashi, Ryosuke Yamamoto, Koji Saida, Keisuke Mizuno, Keizo Fujiwara, Yasushi Naito
Objectives: In performing an open biopsy of a neck mass, an incisional biopsy may increase the risk of cancer cell seeding and dissemination that, ultimately, worsens a patient's survival. The aim of this study was to compare the impact of incisional and excisional biopsies of cervical lymph node metastases of solid tumors on patients' survival. Methods: A retrospective review was made of patients with cervical metastases of solid tumors who underwent an open biopsy for a diagnosis between 2005 and 2015...
April 21, 2018: Japanese Journal of Clinical Oncology
Shingo Miyamoto, Shigenori Kakutani, Yujiro Sato, Akira Hanashi, Yoshitaka Kinoshita, Akira Ishikawa
Pazopanib (Votrient®) is an oral small-molecule multi-kinase inhibitor that primarily inhibits vascular endothelial growth factor receptor-1, -2 and -3, platelet endothelial growth factor receptor-α, and -β, and the stem-cell factor receptor c-kit. In preliminary experiments using angiogenesis models with mice and rabbits, pazopanib inhibited angiogenesis caused by combined vascular endothelial growth factor and basic fibroblast growth factor. Although pazopanib was developed as a therapeutic agent against various tumors, it is currently approved in many countries for advanced soft-tissue sarcoma and renal cell carcinoma...
April 19, 2018: Japanese Journal of Clinical Oncology
Naoki Nakamura, Jiro Kawamori, Osamu Takahashi, Naoto Shikama, Kenji Sekiguchi, Takeo Takahashi, Shingo Kato, Mami Ogita, Atsushi Motegi, Tetsuo Akimoto
Purpose: To clarify the efficacy of palliative radiotherapy for the relief of symptoms due to skin invasion in patients with breast cancer. Materials and methods: We conducted a multi-institutional prospective observational study of patients who received palliative radiotherapy for skin invasion due to a primary lesion or chest wall recurrence. Bleeding/discharge, offensive odor, pain and QOL scores were evaluated before and 1, 3 and 6 months after radiotherapy...
April 19, 2018: Japanese Journal of Clinical Oncology
Yasuo Shinoda, Yoshiyuki Matsui, Hiroyuki Fujimoto
Objective: To evaluate the survival rate and risk factors of distant metastasis in stage I non-seminomatous germ cell tumor (NSGCT) cases without adjuvant treatments. Methods: A national testicular cancer survey of cases newly diagnosed in 2005 and 2008 was conducted by the Japanese Urological Association in 2011. In 159 stage I NSGCT cases, 132 were followed by active surveillance after high orchiectomy. Their recurrence-free survival rate (RFS) was compared with 27 cases that received adjuvant treatments, and clinical and pathological parameters were explored to identify significant risk factors of recurrence...
April 17, 2018: Japanese Journal of Clinical Oncology
Hiroshi Nishio, Takashi Iwata, Hidetaka Nomura, Tohru Morisada, Nobuhiro Takeshima, Hirokuni Takano, Hiroshi Sasaki, Eiji Nakatani, Satoshi Teramukai, Daisuke Aoki
Objective: Liquid-based cytology (LBC) and conventional cytology (CS) are routine diagnostic techniques in cervical cytology, but few studies have compared their diagnostic performances with each other and with histologic diagnosis. This study aimed to compare the diagnostic performances of these techniques in subjects with abnormal cervical cytology of atypical cells of undetermined significance (ASC-US) or worse. Methods: A total of 312 patients diagnosed with ASC-US or worse were enrolled in this prospective study in Japan from 2013 to 2014...
April 13, 2018: Japanese Journal of Clinical Oncology
S Sasazuki, M Inoue, T Shimazu, K Wakai, M Naito, C Nagata, K Tanaka, I Tsuji, Y Sugawara, T Mizoue, K Matsuo, H Ito, A Tamakoshi, N Sawada, T Nakayama, Y Kitamura, A Sadakane, S Tsugane
A comprehensive evidence-based cancer prevention recommendation for Japanese was developed. We evaluated the magnitude of the associations of lifestyle factors and infection with cancer through a systematic review of the literature, meta-analysis of published data, and pooled analysis of cohort studies in Japan. Then, we judged the strength of evidence based on the consistency of the associations between exposure and cancer and biological plausibility. Important factors were extracted and summarized as an evidence-based, current cancer prevention recommendation: 'Cancer Prevention Recommendation for Japanese'...
April 12, 2018: Japanese Journal of Clinical Oncology
Satoshi Inoue, Yoji Saito, Satoru Tsuneto, Etsuko Aruga, Hiroshi Takahashi, Mitsutoshi Uemori
Background: Hydromorphone is a standard opioid analgesic for cancer pain that, prior to this study, was not approved in Japan, where options for opioid switching are limited. We aimed to investigate the efficacy and safety of hydromorphone (DS-7113b) immediate-release tablets in opioid-naïve cancer patients with moderate to severe cancer pain. Methods: Multicenter, active-controlled, randomized, double-blind, parallel-group, non-inferiority study of 183 cancer patients over 20 years of age at 50 clinical sites in Japan...
April 12, 2018: Japanese Journal of Clinical Oncology
Yoichi Naito, Hideaki Takahashi, Kohei Shitara, Wataru Okamoto, Hideaki Bando, Takeshi Kuwata, Yasutoshi Kuboki, Shingo Matsumoto, Izumi Miki, Takeharu Yamanaka, Atsushi Watanabe, Motohiro Kojima
Background: To confirm the feasibility and explore the clinical applicability of amplicon sequencing by next generation sequencing (NGS) of biopsy samples from patients with advanced solid tumors, we conducted a prospective study. Methods: Patients with unresectable, advanced, or recurrent solid tumors were included. Key eligibility criteria were as follows: 20 years or older, any planned systemic therapy, adequate lesion for biopsy, and written informed consent...
April 12, 2018: Japanese Journal of Clinical Oncology
Satoshi Inoue, Yoji Saito, Satoru Tsuneto, Etsuko Aruga, Takeshi Ogata, Mitsutoshi Uemori
Objective: To confirm the morphine to hydromorphone conversion ratio for hydromorphone (DS-7113b) immediate-release tablets in cancer patients who achieved pain control with oral morphine. Methods: This was a multicenter, active-controlled, randomized, double-blind, parallel-group, comparative study (July 2013 to December 2014) at 39 Japanese sites. Seventy-one patients (aged >20 years) who had achieved pain control with morphine 60 mg/day and 90 mg/day were randomly allocated 1:1 to hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:5 or 1:8, respectively, and treated for up to 5 days...
April 9, 2018: Japanese Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"